2026 NPPES data Pulmonary Disease Physician NPI 1124010616 MD
Verify on CMS →

AMIT ANNAMANENI, MD

Pulmonary Disease Physician in SHENANDOAH, Texas. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
4K
Medicare Part D claims · 608 beneficiaries · Pulmonary Disease Physician avg: 1K
Generic prescribing
34%
generic claims · 66% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
77.1335/100
▼ 6 pts below national avg 83.1 · [object Object]
Industry payments
$5.8K
18 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

AMIT ANNAMANENI, MD reported a CMS MIPS final score of 77.1335/100 — below the 83.1 national average — and filed 3,509 Medicare Part D claims in 2023.

77.1335/100
MIPS score · -6 vs avg
4K
Part D claims, 2023
34%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

AMIT ANNAMANENI, MD's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

77 24th percentile higher than 24% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). This entry sits in this band. 80–90: 129,887 scored providers (27%). Above this entry. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

AMIT ANNAMANENI, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about AMIT ANNAMANENI, MD?

Below national average

NPI registry status

Active

Issued 08/19/2005

NPI 1124010616

Primary specialty

Pulmonary Disease Physician

Mid-sized

9,271 US NPIs in this specialty

Medicare Part D claims

3,509 141% vs specialty avg

2023 prescription claims

Specialty avg: 1,457

MIPS final score

77.1335/100 5.966499999999996% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in Texas

How Pulmonary Disease Physician compares to other specialties among Texas providers

Texas providers

Pulmonary Disease Physician share within Texas

1. Pulmonary Disease Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Pulmonary Disease Physician share within Texas

Medicare quality performance — MIPS

AMIT ANNAMANENI, MD's 2023 MIPS final score plotted against the Pulmonary Disease Physician national average

Below national average
MIPS Final Score
77.1335/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Pulmonary Disease Physician) — 77.1335/100 vs national avg 83.1

0%100%National avg83%77.1%
MIPS final score (Pulmonary Disease Physician) — 77.1335/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

AMIT ANNAMANENI, MD appears in the CMS NPPES registry as a Pulmonary Disease Physician provider holding MD credentials at 150 PINE FOREST DR STE 602, SHENANDOAH, TX, 77384, with a listed phone of (281) 440-8430. NPI 1124010616 was issued on 08/19/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ANNAMANENI most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 3,509 prescription claims written by this provider, covering 608 Medicare beneficiaries and totaling roughly $1.3 million in drug spend, split 66% brand-name and 34% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 77.1335/100 for the 2023 performance year (Quality 57.6113, Cost 63.63), compared with the national average of 83.1.

Pulmonary Disease Physician is a mid-sized specialty nationwide, with 9,271 enrolled providers across 53 states and an average of 1,457 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

150 PINE FOREST DR STE 602
SHENANDOAH, TX 77384

Provider Details

NPI 1124010616
Specialty Pulmonary Disease Physician
Credentials MD
Gender Male
NPI Issued 08/19/2005

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

77.1335
Final Score
Avg: 83.1
57.6113
Quality
63.63
Cost

Reporting: Individual

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for AMIT ANNAMANENI, MD. Source: openpaymentsdata.cms.gov.

Total received

$5.8K

Largest payer

INTUITIVE SURGICAL, INC.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — Texas TMB 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~77K Texas medical licensees in 2023 — they are NOT specific to AMIT ANNAMANENI, MD. To verify AMIT ANNAMANENI, MD's current license status, search the TMB public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

344
Total board actions, Texas 2023
Across 334 cases
4.47
Actions per 1,000 licensees
Texas statewide rate
probation
Most common action type
94 cases

TMB publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Texas disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Brand-heavy

AMIT ANNAMANENI, MD — brand share 66.0%
Specialty average (est.)

66% brand-name claims vs 34% generic, on 3,509 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

3,509
Total Claims
$1.3M
Total Drug Cost
608
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
4,395
Total Day Supply
122,539
Brand vs Generic
66% brand / 34% generic
Brand Drug Cost
$1.3M
Antibiotic Claims
103

Patient Demographics

Average Patient Age
74.2 years
Avg HCC Risk Score
2.13
Gender Split
61% female / 39% male
Age Distribution
<65: 67, 65-74: 224, 75-84: 250, 85+: 67

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What AMIT ANNAMANENI, MD prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Albuterol Sulfate Hfa
Albuterol Sulfate
907
Breo Ellipta
Fluticasone/Vilanterol
403
Trelegy Ellipta
Fluticasone/Umeclidin/Vilanter
375
Arnuity Ellipta
Fluticasone Furoate
153
Montelukast Sodium
138
Anoro Ellipta
Umeclidinium Brm/Vilanterol Tr
133
Symbicort
Budesonide/Formoterol Fumarate
132
Fluticasone Propionate
128
Methylprednisolone
109
Flovent Diskus
Fluticasone Propionate
101

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Pulmonary Disease Physician Overview

How AMIT ANNAMANENI, MD fits within the Pulmonary Disease Physician landscape nationally.

9,271
Pulmonary Disease Physician Providers in US
53
States with Pulmonary Disease Physician
1,457
Avg Claims per Provider

AMIT ANNAMANENI, MD's 3,509 claims are above the specialty average of 1,457.

Nearby Pulmonary Disease Physician Providers in Texas

Other clinicians with the same primary specialty enrolled in Texas, drawn from the same CMS NPPES roster as ANNAMANENI.

Compare Pulmonary Disease Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is AMIT ANNAMANENI, MD's specialty?
AMIT ANNAMANENI, MD specializes in Pulmonary Disease Physician and practices in SHENANDOAH, Texas. Credentials: MD.
How much does AMIT ANNAMANENI, MD prescribe under Medicare Part D?
In 2023, AMIT ANNAMANENI, MD wrote 3,509 Medicare Part D claims totaling $1.3M in drug costs for 608 beneficiaries.
What is AMIT ANNAMANENI, MD's Medicare quality score?
AMIT ANNAMANENI, MD has a CMS MIPS Final Score of 77.1335/100 (Quality: 57.6113, Cost: 63.63). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is AMIT ANNAMANENI, MD located?
AMIT ANNAMANENI, MD is located at 150 PINE FOREST DR STE 602, SHENANDOAH, TX, 77384. Phone: (281) 440-8430.
What is AMIT ANNAMANENI, MD's NPI number?
AMIT ANNAMANENI, MD's National Provider Identifier (NPI) is 1124010616, issued on 08/19/2005.
Does AMIT ANNAMANENI, MD prescribe more brand-name or generic drugs?
AMIT ANNAMANENI, MD's prescribing is 66% brand-name and 34% generic drugs by claim count, with $1.3M in brand drug costs.
How many Pulmonary Disease Physician providers are there in the US?
There are 9,271 Pulmonary Disease Physician providers across 53 states in the US. The average Pulmonary Disease Physician provider writes 1,457 Medicare Part D claims per year.
What drugs does AMIT ANNAMANENI, MD prescribe most often?
Based on 2023 Medicare Part D data, AMIT ANNAMANENI, MD's most frequently prescribed drugs include Albuterol Sulfate Hfa, Breo Ellipta, Trelegy Ellipta. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does AMIT ANNAMANENI, MD accept Medicare?
AMIT ANNAMANENI, MD appears in CMS Medicare data with 3,509 Part D claims and 608 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify AMIT ANNAMANENI, MD's credentials?
AMIT ANNAMANENI, MD's NPI is 1124010616 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology